In Vivo T-Cell Depletion (TCD) Does Not Improve Rates of Graft-Versus-Host Disease (GVHD) and Transplantation Outcomes in Patients Undergoing Peripheral Blood Allogeneic Hematopoietic Cell Transplant (AHCT)
Abraham S. Kanate(HonorHealth), Mehdi Hamadani(Medical College of Wisconsin), Sonia Leadmon(West Virginia University), Scot C. Remick(University Hospitals of Cleveland), Laura F. Gibson(West Virginia University), Michael Craig(Edith Cowan University), Jame Abraham(Cleveland Clinic), Pamela Bunner(West Virginia University), William Tse(University of Louisville), Aaron Cumpston(West Virginia University Hospitals), Gerry Hobbs(West Virginia University), Samira Osman(West Virginia University Hospitals)
Cited by 0
Related Papers
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
|Journal of Clinical Oncology|2019|441